Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Allylamine. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN101346345B details a selective primary amine synthesis using ammonia and formaldehyde, offering high purity and cost efficiency for pharmaceutical intermediates manufacturing.
Patent CN110734378B reveals a mild Ni-catalyzed method for high-ee chiral allylamines. Discover cost-effective manufacturing and scalable supply chain solutions.
Patent CN112010910B details a novel iridium-catalyzed synthesis of chiral ferrocene homoallylamines, offering high yields and enantioselectivity for cost-effective pharmaceutical intermediate manufacturing.
Novel iridium-catalyzed synthesis offers high enantioselectivity for pharmaceutical intermediates. Enhances supply chain reliability and reduces manufacturing costs significantly.
Novel photocatalyst-free method for high-purity homoallylamine intermediates using water and visible light, ensuring cost-effective and scalable manufacturing.
Patent CN112552215A details a nickel-catalyzed dehydrogenative coupling for allylamine derivatives, offering cost reduction in pharmaceutical intermediate manufacturing via atom-economical pathways.
Novel copper-catalyzed hydroamination method offers high atom economy and mild conditions for scalable pharmaceutical intermediate production.
Novel ruthenium catalyzed allylation coupling reaction patent offers high yield synthesis for pharmaceutical intermediates with reduced costs and scalable supply chain solutions.
Efficient ruthenium-catalyzed method reduces costs and environmental load for high-purity pharmaceutical intermediates manufacturing supply chain.
Novel visible light method reduces metal waste. Enhances supply chain stability for high-purity pharmaceutical intermediates. Cost-effective scalable production.
Patent CN112441934B discloses a mild copper-catalyzed method for halogenated oxaallylamine synthesis, offering reliable supply and cost reduction in API manufacturing.
Novel copper-catalyzed method for halogenated oxaallylamines. Reduces steps, improves yield for beta-blocker intermediates. Ideal for API manufacturing cost reduction.
Patent CN116444459B enables efficient one-pot synthesis of high-purity pharmaceutical intermediates with enhanced scalability and cost reduction potential for global drug manufacturers.
Patent CN112521289B enables copper-catalyzed synthesis with mild conditions and high atom economy for reliable pharmaceutical intermediate supply chains.
Solve N-aryl imine allylation challenges with this metal-free, air-tolerant process. Achieve 94% yields and eliminate expensive anhydrous equipment. Contact for CDMO scale-up.
Solve N-aryl imine allylation challenges with this metal-free, air-stable method. Achieve 85-94% yields at room temperature, reducing equipment costs and supply chain risks for API synthesis.
Solve chiral amine synthesis challenges with 99% ee, 1% catalyst loading, and gram-scale production for drug development